Squamous cell carcinoma - Kartzinoma Ezkamotsua
☆ Alemaniako Stiftung Warentest-en 2022ko emaitzetan, ModelDerm-ekin kontsumitzaileen gogobetetasuna apur bat txikiagoa izan zen ordaindutako telemedikuntzako kontsultekin baino.
Squamous cell carcinoma well differentiated ― Aldameneko keratosi aktiniko bat ikusten da.
References
Squamous cell carcinoma (SCC) Estatu Batuetako larruazaleko minbizi ohikoena bigarrena da, basal cell carcinoma ren atzetik. Normalean actinic keratosis izeneko minbizi aurreko lesioetatik abiatzen da, eta gorputzeko beste ataletara heda daiteke. Kausa nagusia eguzkiaren erradiazio ultramorearen (UV) esposizioa da, denborarekin pilatzen dena. Tratamenduak normalean kentzea kirurgikoa dakar, batez ere buruan eta lepoan SCCrako. Erradioterapia aukera bat da adineko pazienteentzat edo ebakuntzarik egin ezin dutenentzat. Immunodepresioak SCC izateko arriskua areagotzen du. Arraroa bada ere, SCC hedatu daiteke, batez ere immunitate-sistema ahulduta duten pazienteetan. Aldizkako azterketak eta eguzki babesa garrantzitsuak dira SCC dutenentzat.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Cutaneous squamous cell carcinoma (CSCC) pertsonen artean bigarren minbizi ohikoena da, eta bere kopuruak gora egiten ari dira. CSCC normalean portaera kliniko onbera erakusten duen arren, lokalean eta gorputzeko beste ataletara heda daiteke. Zientzialariek CSCC garapenean parte hartzen duten bide espezifikoak identifikatu dituzte, tratamendu berriak ekarriz. Mutazio-kopuru handiak eta immunodeprimitutako pazienteen arrisku handitzeak immunoterapia garatzea bultzatu du. Berrikuspen honek CSCCren sustrai genetikoak eta molekula zehatzak eta sistema immunologikoa bideratzen dituzten azken tratamenduak aztertzen ditu.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
○ Diagnostikoa eta Tratamendua
#Dermoscopy
#Skin biopsy